Literature DB >> 19204195

Anthracyclines and early breast cancer: the end of an era?

Luca Gianni, Pinuccia Valagussa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19204195     DOI： 10.1200/JCO.2008.20.1640

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Potentiation of the growth inhibition activity of 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) by Herceptin in SKBR-3 human breast cancer cells.

Authors:  Yuan-Wan Sun; Ting-Kuang Niu; Jin-Ming Yang; Chul-Hoon Kwon; Kuen-Yuan Chen; Kun-Ming Chen
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

2.  A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis.

Authors:  Mara Lecchi; Paolo Verderio; Vera Cappelletti; Francesca De Santis; Biagio Paolini; Melissa Monica; Sabina Sangaletti; Serenella Maria Pupa; Marilena Valeria Iorio; Giulia Bianchi; Massimiliano Gennaro; Giovanni Fucà; Filippo De Braud; Elda Tagliabue; Massimo Di Nicola
Journal:  Mol Oncol       Date:  2021-02-19       Impact factor: 6.603

3.  Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.

Authors:  S Aggarwal; A Vaid; A Ramesh; Purvish M Parikh; S Purohit; B Avasthi; S Gupta; S Ranjan; V Kaushal; S Salim; R Singh; S Minhas; D Doval
Journal:  South Asian J Cancer       Date:  2018 Apr-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.